NEW YORK (GenomeWeb News) — PerkinElmer said today it will distribute to drug companies worldwide a luminescent cell-based assay made by Italian company Axxam.
The companies also agreed to create a joint R&D program to develop Photina GPCR and ion-channel lines to profile compounds and in high-throughput screening studies.
PerkinElmer said terms of the deal call for it to distribute the Photina photoprotein system, which is used to screen drug-discovery targets such as G-protein coupled receptors and ion channels.
The deal allows Axxam to continue to use Photina in its own drug-development service to third-party clients, the company said.
PerkinElmer said the agreement with Axxam enhances the capabilities it gained through its December acquisition of Euroscreen products and its own AequoScreen cellular assay platform.